![]() × Maximilian Diehn MD, PhD Scientific Advisor, Founder, Board Member His clinical research is focused on diagnostic, prognostic, and predictive biomarkers and translating discoveries from the laboratory to the clinic using cutting tools in data science. Clinically, he is a practicing medical oncologist specializing in the care of patients with lymphoma, including diffuse large B-cell lymphomas (DLBCL). ![]() Diehn’s group, his research group at Stanford University has a long history of developing cancer genomic t echniques, including for ultra-sensitive and non-invasive detection of tumor-derived cell-free DNA. Alizadeh has a significant history of research and accomplishments in cancer genomics, beginning with the original development of microarra y gene expression profiling for cancer classification starting with lymphomas, and advancing to multiple tumor types. × Ash Alizadeh MD, PhD Chief Medical Advisor, FounderĪsh Alizadeh (M.D./Ph.D.) is a co-founder of Foresight Diagnostics and Professor of Medicin e (Oncology) at Stanford University where he leads the Cancer Genomics program at the Stanford Cancer Institute. from Indian Institute of Technology, Delhi. Earlier in his career, Mukul was a management consultant with PRTM (acquired by PriceWaterhouseCoopers ) with a focus on strategy and operational excellence for Biotech/Pharma and Medical Device and Diagnostic clients. He has also held commercial strategy, brand marketing, and portfolio management roles at MedImmune (acquired by AstraZeneca), GlaxoSmithKline and Genentech. ![]() ![]() Before Forty Seven, he held the roles of VP of Business Development at Revance, Senior Director of Corporate Development and Strategy at Anacor (acquired by Pfizer), and Director of Global BD&L at Forest Pharmaceuticals (acquired by Allergan, now Abbvie ). Prior to joining Foresight, Mukul was Vice President of Corporate Development at Forty Seven, Inc (acquired by Gilead in 2020). Mukul has over 20 years of experience in corporate development, fina nce, and strategy. Mukul Agarwal is the CFO & CBO of Foresight Diagnostics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |